Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial 70S ribosomal initiation complex is a transient but crucial macromolecular assembly that represents the rate-limiting first step of protein biosynthesis in bacteria. It is composed of the small (30S) and large (50S) ribosomal subunits, messenger RNA (mRNA), the initiator N-formylmethionyl-tRNA (fMet-tRNA), and three protein initiation factors: IF1, IF2, and IF3 (PMC: 5952554). This complex coordinates the precise alignment of the start codon with the initiator tRNA, ensuring that the genetic message is read in the correct frame. Because bacterial 70S ribosomes are structurally distinct from eukaryotic 80S ribosomes, they are highly effective targets for various antibiotic classes, particularly oxazolidinones and aminoglycosides (PMC: 4434222). Disruption of the complex formation or stability effectively halts the synthesis of essential bacterial proteins, leading to cell death or growth inhibition. However, the evolutionary similarity between bacterial ribosomes and human mitochondrial ribosomes poses a challenge for drug safety, potentially leading to side effects like myelosuppression and ototoxicity. Resistance to these drugs often arises from point mutations in the ribosomal RNA (rRNA) or enzymatic modification of the binding site.
Antibiotics targeting this complex typically inhibit protein synthesis by binding to either the 30S or 50S ribosomal subunits, thereby preventing their assembly into a functional 70S initiation complex or blocking the correct positioning of the initiator fMet-tRNA (PubMed: 11110904, PMC: 4434222). For example, oxazolidinones bind to the 50S subunit to sterically hinder the joining of the 30S initiation complex, while aminoglycosides bind the 16S rRNA in the 30S subunit to interfere with the fidelity of initiation and induce mRNA misreading (StatPearls: NBK544304).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 70S ribosomal initiation complex (70S IC) (70S IC).